Under US pressure, Indian government is getting its act together on IP matters

27 October 2014
gateway-of-india-big

The pressure from the US government on India seems to be working. With India's intellectual property rights (IPR) regime facing flak, and the USA launching an out-of-cycle review of India's IPR regime, the Department of Industrial Policy and Promotion (DIPP) has set up a think-tank to draft a National Intellectual Property Rights Policy. Work is also on to set up IPR courts to fast track cases, reports The Pharma Letter’s India correspondent.

Prabha Sridevan, a former Judge of the Madras High Court, who was also the former chairman of the Intellectual Property Appellate Board, is to lead the think-tank, and help with the formation of the new policy.

“A pressurized Indian government is getting its act together. Through the new policy, India is aiming to brand itself as pro-IP. And by setting up more courts, the government is keen to show that it means business in resolving IPR cases,'' said an official at the DIPP, seeking anonymity.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical